

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following drug types best reflects the mechanism of action of nirogacestat?**
 - a. EZH2 inhibitor
 - b. KIT/PDGFR α inhibitor
 - c. Small-molecule gamma secretase inhibitor**
- 2. What was the objective response rate in the initial analyses of the Phase III DeFI study evaluating nirogacestat versus placebo for patients with progressing desmoid tumors?**
 - a. 25%
 - b. 41%**
 - c. 68%
- 3. Which of the following outcomes best describes the major progression-free survival findings from the Phase III RINGSIDE trial evaluating varegacestat versus placebo for patients with progressing desmoid tumors?**
 - a. Inferior outcomes with varegacestat
 - b. A numerical but nonsignificant improvement with varegacestat
 - c. A statistically significant improvement with varegacestat**
- 4. Which of the following adverse events was most commonly reported among patients receiving varegacestat for progressing desmoid tumors in the Phase III RINGSIDE trial?**
 - a. Diarrhea**
 - b. Fatigue
 - c. Rash
 - d. Nausea